

July 14, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai - 400 051

**Scrip code: 512529**

**Symbol: SEQUENT**

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Re-appointment of Non-Executive Independent Directors.**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III, Part A, Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we wish to inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the re-appointment of Dr. Kamal Sharma (DIN: 00209430) and Mr. Milind Sarwate (DIN: 00109854) as Non-Executive Independent Director of the Company for a second term of five consecutive years from August 25, 2025, to August 24, 2030, subject to approval of the shareholders.

The details under Regulation 30 of the Listing Regulations read along with SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and the SEBI circular no. SEBI/HO/CFD/CFD-PoD 2/CIR/P/2024/185 dated December 31, 2024, are enclosed as "Annexure A".

The aforesaid information is also being made available on the website of the Company at: <https://sequent.in/investor-relation/>

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,  
For **Sequent Scientific Limited**

**Yoshita Vora**  
**Company Secretary & Compliance Officer**  
**Encl: As above**

**SeQuent Scientific Limited**

**Registered Office:** 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

**Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

**Tel No.:** +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)

**Annexure – A**

**Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

<b>Dr. Kamal Sharma [DIN: 00209430]</b>		
<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
<b>a.</b>	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	The Board of Directors have, based on the recommendation of the Nomination and Remuneration Committee, approved the reappointment of Dr. Kamal Sharma (DIN: 00209430) as an Independent Director of the Company for a second term of five consecutive years from August 25, 2025, to August 24, 2030, subject to approval of the shareholders.
<b>b.</b>	Date of Appointment / reappointment / cessation (as applicable) and term of appointment / reappointment	Re-appointed as Non-Executive Independent Director of the Company for a second term of five consecutive years from August 25, 2025, to August 24, 2030, subject to approval of the shareholders.
<b>c.</b>	Brief Profile (in case of appointment)	<p>Dr. Kamal Sharma has over five decades of professional experience in executive positions in the Chemical and Pharmaceutical industries and has essayed a wide variety of roles in operations, corporate development and executive management. As the Managing Director of Lupin for a decade between 2003-13, he was instrumental in Lupin achieving leadership position in key markets and businesses, transforming it into one of the largest and fastest growing pharmaceutical companies globally. Previously, he also served as President &amp; Chief Executive of the Life Sciences and speciality group and Member of the Management Board at RPG Enterprises.</p> <p>Dr. Sharma received a bachelor's degree in chemical engineering from IIT Kanpur, a post graduate diploma in Industrial Management from Jamnalal Bajaj Institute of Management Studies and a PhD in Economics from IIT, Mumbai. He has also attended Advanced Management Program (AMP) at Harvard Business School, Boston.</p>
<b>d.</b>	Disclosure of relationships between directors (in case of appointment of a director)	Dr. Kamal Sharma is not related to any Director on the Board of the Company.
<b>e.</b>	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Dr. Kamal Sharma is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

**SeQuent Scientific Limited**

**Registered Office:** 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

**Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

**Tel No.:** +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)

<b>Mr. Milind Sarwate [DIN:00109854]</b>		
<b>Sr.No.</b>	<b>Particulars</b>	<b>Details</b>
<b>a.</b>	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	The Board of Directors have, based on the recommendation of the Nomination and Remuneration Committee, approved the reappointment of Mr. Milind Sarwate (DIN: 00109854) as an Independent Director of the Company for a second term of five consecutive years from August 25, 2025, to August 24, 2030, subject to approval of the shareholders.
<b>b.</b>	Date of Appointment/ reappointment / cessation (as applicable) and term of appointment /reappointment	Re-appointed as Non- Executive Independent Director of the Company for a second term of five consecutive years from August 25, 2025, to August 24, 2030, subject to approval of the shareholders.
<b>c.</b>	Brief Profile (in case of appointment)	<p>Milind Sarwate, Founder of Increate, is an Advisor, Mentor, Independent Director, &amp; ESG Contributor.</p> <p>Increate (meaning “Uncreated” or “Undiscovered”, <a href="http://increate.in">increate.in</a>) works towards business and social value creation, with a focus on capability-building, governance &amp; social aspects of ESG.</p> <p>Milind’s independent directorships include Asian Paints, Mahindra Finance, CEAT, Nykaa, and Hexaware. He specializes in audit committee roles. He has been on listed company boards since 2005.</p> <p>His previous board memberships include Mindtree and International Paper.</p> <p>His 42-year experience includes long stints as CFO and CHRO in Marico &amp; Godrej.</p> <p>He is a Chartered Accountant, Cost Accountant, Company Secretary, and a CII-Fulbright Fellow.</p>
<b>d.</b>	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Milind Sarwate is not related to any Director on the Board of the Company.
<b>e.</b>	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Milind Sarwate is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

**SeQuent Scientific Limited**

**Registered Office:** 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

**Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

**Tel No.:** +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)